Research advances of fusion proteins in osteoclasts

doi:10.3877/cma.j.issn.1674-1366.2020.04.002

Abstract

Abstract:

Osteoclasts are multinucleated giant cells with bone resorption capacity. During osteoclast differentiation, cytokines stimulate the expression of fusion proteins on cell surface of osteoclast precursors, such as dendritic cell-specific transmembrane protein (DC-STAMP) , osteoclast-stimulatory transmembrane protein (OC-STAMP) , etc., which lay foundation for osteoclast fusion. Under pathological conditions, abnormal secretion of cytokines leads to increased expression of osteoclast fusion proteins, which promotes the fusion of osteoclast precursors to form osteoclasts with stronger bone resorption capacity. Aberrant expression of osteoclast fusion proteins is a prerequisite for pathological bone destruction caused by osteoclasts. Elucidation of the mechanisms underlying the roles of fusion proteins in osteoclasts is of great significance for the intervention of bone destructive diseases. In this article, we expound the research status of osteoclast fusion proteins to provide references for the further study of osteoclast-related bone destructive diseases.

Key words: Osteoclasts, Cell fusion, Membrane proteins

Junpan Luo, Jiarui Lu, Jingjing Quan. Research advances of fusion proteins in osteoclasts[J]. Chinese Journal of Stomatological Research(Electronic Edition), 2020, 14(04): 207-213.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhkqyxyjzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1366.2020.04.002

https://zhkqyxyjzz.cma-cmc.com.cn/EN/Y2020/V14/I04/207

Figures/Tables 1

References 72

[1]	Levaot N，Ottolenghi A，Mann M，et al. Osteoclast fusion is initiated by a small subset of RANKL-stimulated monocyte progenitors，which can fuse to RANKL-unstimulated progenitors[J]. Bone，2015，79:21-28. DOI：10.1016/j.bone.2015.05.021.
[2]	Chiu YH，Ritchlin CT. DC-STAMP：A Key Regulator in Osteoclast Differentiation[J]. J Cell Physiol，2016，231(11):2402-2407. DOI：10.1002/jcp.25389.
[3]	Miyamoto H，Suzuki T，Miyauchi Y，et al. Osteoclast stimulatory transmembrane protein and dendritic cell-specific transmembrane protein cooperatively modulate cell-cell fusion to form osteoclasts and foreign body giant cells[J]. J Bone Miner Res，2012，27(6):1289-1297. DOI：10.1002/jbmr.1575.
[4]	Lee SH，Rho J，Jeong D，et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation[J]. Nat Med，2006，12(12):1403-1409. DOI：10.1038/nm1514.
[5]	Lundberg P，Koskinen C，Baldock PA，et al. Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPα-interaction[J]. Biochem Biophy Res Commun，2007，352(2):444-448. DOI：10.1016/j.bbrc.2006.11.057.
[6]	Fiorino C，Harrison RE. E-cadherin is important for cell differentiation during osteoclastogenesis[J]. Bone，2016，86:106-118. DOI：10.1016/j.bone.2016.03.004.
[7]	Nakamura H，Nakashima T，Hayashi M，et al. Global epigenomic analysis indicates protocadherin-7 activates osteoclastogenesis by promoting cell-cell fusion[J]. Biochem Biophys Res Commun，2014，455(3-4):305-311. DOI：10.1016/j.bbrc.2014.11.009.
[8]	Lee JH，Hsieh CF，Liu HW，et al. Lipid raft-associated stomatin enhances cell fusion[J]. FASEB J，2017，31(1):47-59. DOI：10.1096/fj.201600643R.
[9]	Liao HJ，Tsai HF，Wu CS，et al. TRAIL inhibits RANK signaling and suppresses osteoclast activation via inhibiting lipid raft assembly and TRAF6 recruitment[J]. Cell Death Dis，2019，10(2):77. DOI：10.1038/s41419-019-1353-3.
[10]	Takahashi A，Kukita A，Li YJ，et al. Tunneling nanotube formation is essential for the regulation of osteoclastogenesis[J]. J Cell Biochem，2013，114(6):1238-1247. DOI：10.1002/jcb.24433.
[11]	Dupont M，Souriant S，Lugo-Villarino G，et al. Tunneling Nanotubes：Intimate Communication between Myeloid Cells[J]. Front Immunol，2018，9:43. DOI：10.3389/fimmu.2018.00043.
[12]	Pennanen P，Alanne MH，Fazeli E，et al. Diversity of actin architecture in human osteoclasts：network of curved and branched actin supporting cell shape and intercellular micrometer-level tubes[J]. Mol Cell Biochem，2017，432(1):131-139. DOI：10.1007/s11010-017-3004-2.
[13]	Takito J，Nakamura M. Precursors linked via the zipper-like structure or the filopodium duringthe secondary fusion of osteoclasts[J]. Commun Integr Biol，2012，5(5):453-457. DOI：10.4161/cib.20980.
[14]	Takito J，Otsuka H，Inoue S，et al. Symmetrical retrograde actin flow in the actin fusion structure is involved in osteoclast fusion[J]. Biol Open，2017，6(7):1104-1114. DOI：10.1242/bio.025460.
[15]	Wang D，Gu J，Feng L，et al. 1-α，25-dihydroxyvitamin D₃ potentiates avian osteoclast activation by increasing the formation of zipper-like structure via Src/Rac1 signaling[J]. Biochem Biophys Res Commun，2018，501(2):576-583. DOI：10.1016/j.bbrc.2018.05.048.
[16]	Fu J，Li S，Feng R，et al. Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease[J]. J Clin Invest，2016，126(5):1759-1772. DOI：10.1172/JCI80276.
[17]	Arioka M，Takahashi-Yanaga F，Tatsumoto N，et al. Inorganic phosphate-induced impairment of osteoclast cell-cell fusion by the inhibition of AP-1-mediated DC-STAMP expression[J]. Biochem Biophys Res Commun，2017，493(1):9-13. DOI：10.1016/j.bbrc.2017.09.096.
[18]	Islam R，Bae HS，Yoon WJ，et al. Pin1 regulates osteoclast fusion through suppression of the master regulator of cell fusion DC-STAMP[J]. J Cell Physiol，2014，229(12):2166-2174. DOI：10.1002/jcp.24679.
[19]	Islam R，Yoon WJ，Ryoo HM. Pin1，the Master Orchestrator of Bone Cell Differentiation[J]. J Cell Physiol，2017，232(9):2339-2347. DOI：10.1002/jcp.25442.
[20]	Kanemoto S，Kobayashi Y，Yamashita T，et al. Luman is involved in osteoclastogenesis through the regulation of DC-STAMP expression，stability and localization[J]. J Cell Sci，2015，128(23):4353-4365. DOI：10.1242/jcs.176057.
[21]	Zeng Z，Zhang C，Chen J. Lentivirus-mediated RNA interference of DC-STAMP expression inhibits the fusion and resorptive activity of human osteoclasts[J]. J Bone Miner Metab，2013，31(4):409-416. DOI：10.1007/s00774-013-0434-0.
[22]	Wisitrasameewong W，Kajiya M，Movila A，et al. DC-STAMP Is an Osteoclast Fusogen Engaged in Periodontal Bone Resorption[J]. J Dent Res，2017，96(6):685-693. DOI：10.1177/0022034517690490.
[23]	Iwasaki R，Ninomiya K，Miyamoto K，et al. Cell fusion in osteoclasts plays a critical role in controlling bone mass and osteoblastic activity[J]. Biochem Biophy Res Commun，2008，377(3):899-904. DOI：10.1016/j.bbrc.2008.10.076.
[24]	Mensah KA，Ritchlin CT，Schwarz EM. RANKL induces heterogeneous DC-STAMP（lo）and DC-STAMP（hi）osteoclast precursors of which the DC-STAMP（lo）precursors are the master fusogens[J]. J Cell Physiol，2010，223(1):76-83. DOI：10.1002/jcp.22012.
[25]	Søe K，Hobolt-Pedersen AS，Delaisse JM. The elementary fusion modalities of osteoclasts[J]. Bone，2015，73:181-189. DOI：10.1016/j.bone.2014.12.010.
[26]	Chiu YH，Schwarz E，Li D，et al. Dendritic Cell-Specific Transmembrane Protein（DC-STAMP）Regulates Osteoclast Differentiation via the Ca²⁺/NFATc1 Axis[J]. J Cell Physiol，2017，232(9):2538-2549. DOI：10.1002/jcp.25638.
[27]	Møller AM，Delaissé JM，Søe K. Osteoclast Fusion：Time-Lapse Reveals Involvement of CD47 and Syncytin-1 at Different Stages of Nuclearity[J]. J Cell Physiol，2017，232(6):1396-1403. DOI：10.1002/jcp.25633.
[28]	Verma SK，Leikina E，Melikov K，et al. Cell-surface phosphatidylserine regulates osteoclast precursor fusion[J]. J Biol Chem，2018，293(1):254-270. DOI：10.1074/jbc.M117.809681.
[29]	Belibasakis GN，Emingil G，Saygan B，et al. Gene expression of transcription factor NFATc1 in periodontal diseases[J]. APMIS，2011，119(3):167-172. DOI：10.1111/j.1600-0463.2010.02706.x.
[30]	Laurier E，Amiable N，Gagnon E，et al. Effect of a rare genetic variant of TM7SF4 gene on osteoclasts of patients with Paget′s disease of bone[J]. BMC Med Genet，2017，18(1):133. DOI：10.1186/s12881-017-0495-3.
[31]	Sultana MA，Pavlos NJ，Ward L，et al. Targeted sequencing of DCSTAMP in familial Paget′s disease of bone[J]. Bone Rep，2019，10:100198. DOI：10.1016/j.bonr.2019.100198.
[32]	Gross C，Weber M，Creutzburg K，et al. Osteoclast profile of medication-related osteonecrosis of the jaw secondary tobisphosphonate therapy：a comparison with osteoradionecrosis and osteomyelitis[J]. J Transl Med，2017，15(1):128. DOI：10.1186/s12967-017-1230-8.
[33]	Witwicka H，Hwang SY，Reyes-Gutierrez P，et al. Studies of OC-STAMP in Osteoclast Fusion：A New Knockout Mouse Model，Rescue of Cell Fusion，and Transmembrane Topology[J]. PLoS ONE，2015，10(6):e0128275. DOI：10.1371/journal.pone.0128275.
[34]	Yang M，Birnbaum MJ，MacKay CA，et al. Osteoclast stimulatory transmembrane protein（OC-STAMP），a novel protein induced by RANKL that promotes osteoclast differentiation[J]. J Cell Physiol，2008，215(2):497-505. DOI：10.1002/jcp.21331.
[35]	Kim MH，Park M，Baek SH，et al. Molecules and signaling pathways involved in the expression of OC-STAMP during osteoclastogenesis[J]. Amino Acids，2011，40(5):1447-1459. DOI：10.1007/s00726-010-0755-4.
[36]	Yuan H，He J，Zhang G，et al. Osteoclast stimulatory transmembrane protein induces a phenotypic switch in macrophage polarization suppressing an M1 pro-inflammatory state[J]. Acta Biochim Biophys Sin（Shanghai），2017，49(10):935-944. DOI：10.1093/abbs/gmx092.
[37]	Hwang YS，Ma GT，Park KK，et al. Lysophosphatidic acid stimulates osteoclast fusion through OC-STAMP and P2X7 receptor signaling[J]. J Bone Miner Metab，2014，32(2):110-122. DOI：10.1007/s00774-013-0470-9.
[38]	Ishii T，Ruiz-Torruella M，Ikeda A，et al. OC-STAMP promotes osteoclast fusion for pathogenic bone resorption in periodontitis via up-regulation of permissive fusogen CD9[J]. FASEB J，2018，32(7):4016-4030. DOI：10.1096/fj.201701424R.
[39]	Mazhab-Jafari MT，Rohou A，Schmidt C，et al. Atomic model for the membrane-embedded VO motor of a eukaryotic V-ATPase[J]. Nature，2016，539(7627):118-122. DOI：10.1038/nature19828.
[40]	Kim K，Lee SH，Ha Kim J，et al. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein（DC-STAMP）[J]. Mol Endocrinol，2008，22(1):176-185. DOI：10.1210/me.2007-0237.
[41]	Zhao X，Ning L，Xie Z，et al. The Novel p38 Inhibitor，Pamapimod，Inhibits Osteoclastogenesis and Counteracts Estrogen-Dependent Bone Loss in Mice[J]. J Bone Miner Res，2019，34(5):911-922. DOI：10.1002/jbmr.3655.
[42]	Gong R，Peng X，Kang S，et al. Structural characterization of the fusion core in syncytin，envelope protein of human endogenous retrovirus family W[J]. Biochem Biophys Res Commun，2005，331(4):1193-1200. DOI：10.1016/j.bbrc.2005.04.032.
[43]	Søe K，Andersen TL，Hobolt-Pedersen AS，et al. Involvement of human endogenous retroviral syncytin-1 in human osteoclast fusion[J]. Bone，2011，48(4):837-846. DOI：10.1016/j.bone.2010.11.011.
[44]	Mbalaviele G，Chen H，Boyce BF，et al. The role of cadherin in the generation of multinucleated osteoclasts from mononuclear precursors in murine marrow[J]. J Clin Invest，1995，95(6):2757-2765. DOI：10.1172/JCI117979.
[45]	Sun Q，Liu C，Bai X，et al. Cell-substrate traction force regulates the fusion of osteoclast precursors through cell-cell interaction[J]. Biomech Model Mechanobiol，2020，19(2):481-492. DOI：10.1007/s10237-019-01223-4.
[46]	Quan J，Du Q，Hou Y，et al. Utilization of E-cadherin by monocytes from tumour cells plays key roles in the progression of bone invasion by oral squamous cell carcinoma[J]. Oncol Rep，2017，38(2):850-858. DOI：10.3892/or.2017.5749.
[47]	Takeda Y，Tachibana I，Miyado K，et al. Tetraspanins CD9 and CD81 function to prevent the fusion of mononuclear phagocytes[J]. J Cell Biol，2003，161(5):945-956. DOI：10.1083/jcb.200212031.
[48]	Reyes R，Monjas A，Yánez-Mó M，et al. Different states of integrin LFA-1 aggregation are controlled through its association with tetraspanin CD9[J]. Biochim Biophys Acta，2015，1853(10 Pt A):2464-2480. DOI：10.1016/j.bbamcr.2015.05.018.
[49]	Ishii M，Iwai K，Koike M，et al. RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis[J]. J Bone Miner Res，2006，21(6):965-976. DOI：10.1359/jbmr.060308.
[50]	Yi T，Kim HJ，Cho JY，et al. Tetraspanin CD9 regulates osteoclastogenesis via regulation of p44/42 MAPK activity[J]. Biochem Biophys Res Commun，2006，347(1):178-184. DOI：10.1016/j.bbrc.2006.06.061.
[51]	Iwai K，Ishii M，Ohshima S，et al. Abundant expression of tetraspanin CD9 in activated osteoclasts in ovariectomy-induced osteoporosis and in bone erosions of collagen-induced arthritis[J]. Rheumatol Int，2008，28(3):225-231. DOI：10.1007/s00296-007-0424-4.
[52]	Shi Y，Zhou W，Cheng L，et al. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells[J]. Cell Death Differ，2017，24(1):167-180. DOI：10.1038/cdd.2016.110.
[53]	Hu J，Li X，Chen Y，et al. The protective effect of WKYMVm peptide on inflammatory osteolysis through regulating NF-κB and CD9/gp130/STAT3 signalling pathway[J]. J Cell Mol Med，2020，24(2):1893-1905. DOI：10.1111/jcmm.14885.
[54]	Monteagudo S，Cornelis FMF，Aznar-Lopez C，et al. DOT1L safeguards cartilage homeostasis and protects against osteoarthritis[J]. Nat Commun，2017，8:15889. DOI：10.1038/ncomms15889.
[55]	Gao Y，Ge W. The histone methyltransferase DOT1L inhibits osteoclastogenesis and protects against osteoporosis[J]. Cell Death Dis，2018，9(2):33. DOI：10.1038/s41419-017-0040-5.
[56]	Hobolt-Pedersen AS，Delaissé JM，Søe K. Osteoclast fusion is based on heterogeneity between fusion partners[J]. Calcif Tissue Int，2014，95(1):73-82. DOI：10.1007/s00223-014-9864-5.
[57]	Søe K，Andersen TL，Hinge M，et al. Coordination of Fusion and Trafficking of Pre-osteoclasts at the Marrow-Bone Interface[J]. Calcif Tissue Int，2019，105(4):430-445. DOI：10.1007/s00223-019-00575-4.
[58]	Koduru SV，Sun B，Walker JM，et al. The contribution of cross-talk between the cell-surface proteins CD36 and CD47-TSP-1 in osteoclast formation and function[J]. J Biol Chem，2018，293(39):15055-15069. DOI：10.1074/jbc.RA117.000633.
[59]	Ishii M，Saeki Y. Osteoclast cell fusion：mechanisms and molecules[J]. Mod Rheumatol，2008，18(3):220-227. DOI：10.1007/s10165-008-0051-2.
[60]	Sunagawa M，Mii S，Enomoto A，et al. Suppression of skin tumorigenesis in CD109-deficient mice[J]. Oncotarget，2016，7(50):82836-82850. DOI：10.18632/oncotarget.12653.
[61]	Zhang JM，Murakumo Y，Hagiwara S，et al. CD109 attenuates TGF-β1 signaling and enhances EGF signaling in SK-MG-1 human glioblastoma cells[J]. Biochem Biophys Res Commun，2015，459(2):252-258. DOI：10.1016/j.bbrc.2015.02.093.
[62]	Wang Y，Inger M，Jiang H，et al. CD109 plays a role in osteoclastogenesis[J]. PLoS ONE，2013，8(4):e61213. DOI：10.1371/journal.pone.0061213.
[63]	Mii S，Hoshino A，Enomoto A，et al. CD109 deficiency induces osteopenia with an osteoporosis-like phenotype in vivo[J]. Genes Cells，2018，23(7):590-598. DOI：10.1111/gtc.12593.
[64]	Fennen M，Pap T，Dankbar B. Smad-dependent mechanisms of inflammatory bone destruction[J]. Arthritis Res Ther，2016，18(1):279. DOI：10.1186/s13075-016-1187-7.
[65]	Cui W，Cuartas E，Ke J，et al. CD200 and its receptor，CD200R，modulate bone mass via the differentiation of osteoclasts[J]. Proc Natl Acad Sci U S A，2007，104(36):14436-14441. DOI：10.1073/pnas.0702811104.
[66]	Varin A，Pontikoglou C，Labat E，et al. CD200R/CD200 inhibits osteoclastogenesis：new mechanism of osteoclast control by mesenchymal stem cells in human[J]. PloS One，2013，8(8):e72831. DOI：10.1371/journal.pone.0072831.
[67]	Guo Y，Yuan Y，Wu L，et al. BMP-IHH-mediated interplay between mesenchymal stem cells and osteoclasts supports calvarial bone homeostasis and repair[J]. Bone Res，2018，6(1):30. DOI：10.1038/s41413-018-0031-x.
[68]	Choi SJ，Han JH，Roodman GD. ADAM8：a novel osteoclast stimulating factor[J]. J Bone Miner Res，2001，16(5):814-822. DOI：10.1359/jbmr.2001.16.5.814.
[69]	Namba K，Nishio M，Mori K，et al. Involvement of ADAM9 in multinucleated giant cell formation of blood monocytes[J]. Cell Immunol，2001，213(2):104-113. DOI：10.1006/cimm.2001.1873.
[70]	Elavarasu S，Suthanthiran T，Thangavelu A，et al. Comparative analysis of gingival crevicular fluid a disintegrin and metalloproteinase 8 levels in health and periodontal disease：A clinic-biochemical study[J]. J Pharm Bioallied Sci，2015，7(Suppl2):S470-S473. DOI：10.4103/0975-7406.163507.
[71]	Iwai K，Ishii M，Ohshima S，et al. Expression and function of transmembrane-4 superfamily（tetraspanin）proteins in osteoclasts：reciprocal roles of tspan-5 and NET-6 during osteoclastogenesis[J]. Allergol Int，2007，56(4):457-463. DOI：10.2332/allergolint.O-07-488.
[72]	Pata M，Vacher J. Ostm1 Bifunctional Roles in Osteoclast Maturation：Insights From a Mouse Model Mimicking a Human OSTM1 Mutation[J]. J Bone Miner Res，2018，33(5):888-898. DOI：10.1002/jbmr.3378.

Please choose a citation manager

Content to export